According to CSC Securities’ research report, several brain-computer interface (BCI) companies have recently expanded their product pipeline or are preparing to apply for Class III medical device certification registration. It is projected that both national and local governments will roll out further supportive policies. Spurred by these initiatives, the clinical adoption and commercialization of BCI technologies are expected to accelerate, creating new investment opportunities. Since the start of the year, the market valuations of listed companies involved in BCI have surged. This upward trend is anticipated to fuel increased financing activity in the primary market and drive a reevaluation of valuations for related firms, fostering a mutually beneficial dynamic between capital investment and industrial growth. Investors are advised to focus on companies with robust independent R&D capabilities, those engaged in deep collaborations with leading universities and research institutions, as well as companies with strategic investments or partnerships with renowned BCI enterprises in the primary market.